Gufic Biosciences Limited · NSE:GUFICBIO
Gufic Biosciences — Q3 FY2026 Earnings Presentation
34 slides from Gufic Biosciences's earnings presentation, Feb 13, 2026
Slide 1: Exchange cover letter for investor presentation
26/LG/SE/FEB/2026/GBSL February 13, 2026 To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex, Dalal Street, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 509079 Scrip Symbol: GUFICBIO Subject: Investor Present
Slide 2: Delivering Care & Cure – Investor Presentation Q3FY2025
Delivering Care & Cure Investor Presentation For Q3FY2025
Slide 3: Safe Harbor
Safe Harbor This presentation has been pr epar ed by and is the sole r esponsibility of Gufic B iosciences Limi ted (the “ Com pany” ). By accessing this pr ese ntation, you ar e agr eeing to be bound by the tr ailing re str ictions. This pr esentation does not constitute or form part of any offer o
Slide 4: Q3 FY26 Business & Financial Highlights
Q3 FY26 Business & Financial Highlights
Slide 5: Indore Facility update: Progress on track as planned
Indore Facility update: Progress on track as planned We have built one of the most advanced lyophilized Timeline of our phased approach injectable facilities, commenced production in Milestone Target Status & Commentary October 2024 Installation & Operational ✅ Completed – facility meets WHO GMP, EU
Slide 6: Hospital Injectable Platform
I. Hospital Injectable Platform. Therapy Focus: Anti-Microbials, Immunology & Cardiac Critical Care A. Critical Care Cluster B. Sparsh Hospital-first execution to widen ICU account coverage and compound molecule- Scaling a hospital + nursing-home platform by tightening execution infrastructure and c
Slide 7: Complex injectable pipeline for the hospital platform
Complex injectable pipeline for the hospital platform Drug Class Unique Advantages Complexity in Manufacturing Domestic Business Breakup Novel β-lactam/β- Targets multi-drug resistant Gram-negative Complex formulation with dual agents requires precise lactamase Inhibitor bacteria; highly effective f
Slide 8: Women's Health Platform
II. Women’s Health Platform. Therapy Focus: Assisted Reproductive Technology(IVF), Immunology & Ortho-gynae A. Ferticare Cluster B. Zenova Scaling a high-science fertility franchise by owning Reproductive Immunology and Upgrading portfolio quality by scaling prescription-led power brands, expanding
Slide 9: Botulinum Toxin Platform
III. Botulinum Toxin Platform. Therapy Focus: Aesthetics & Neurology A. Aesthaderm B. Neurocare Scaling from a toxin brand into a full-stack aesthetics platform by widening Scaling the Therapeutic Toxin Franchise by creating new injectors in guideline- injector creation, strengthening evidence, and
Slide 10: Nutra, Ayurveda & Others
IV. Nutra, Ayurveda & Others. Therapy Focus: Chronic Musculoskeletal Pain & Gastro Nutra, Ayurveda & Others Repositioning the portfolio as a science-led chronic-care platform in pain, arthritis and GI—driving sustainable reach through differentiated formulations and next-gen prescriber ecosystem bui
Slide 11: International Business strategy and regulatory update
V. International Business: Shifting international growth from opportunistic filings to an IP-owned, complex- injectables-led export & licensing engine. 1. Strategy: From Distributor-Led to IP-Owned Markets 3. Regulatory Update Regulated markets momentum (EU): Approvals in Germany for Colistimethat
Slide 12: Near Term Indore Scale Up Plan
V. Near Term Indore Scale Up Plan: Converting complex injectables expertise into a global sales and licensing engine. RA Status--> Key Products with Stringent Countries-Ready Dossiers Strategic Roadmap (3–5 Years) Regulated Market Current Market Size Market Share Goal: Capture 5–10% in identified
Slide 13: Research & Development
Research & Development Update on R&D Update on Selvax • Peptides R&D: Paving the Way for In-house Critical Developing SVX-3001 (humanized anti-CD40 agonist antibody) co-administered intratumorally with IL-2 to API Manufacturing: Our foray into peptides research amplify anti-tumour immune response wh
Slide 14: Strategic Initiatives
Strategic Initiatives Strategic Initiatives that will further amplify growth over the next few years Increase in overall market and market share in Leverage new biological Botulinum Toxin range of Increase market share in technology platform to products through Commercialization of contract manufact
Slide 15: Profit & Loss Statement
Profit & Loss Statement Particulars Q3 FY26 Q2 FY26 Q3 FY25 9M FY26 9M FY25 (in Rs. Crore) Total Revenue 231.1 230.4 207.8 688.4 614.8 EBITDA 37.1 37.9 35.8 108.2 111.6 EBITDA Margin % 16.05% 16.45% 17.23% 15.72% 18.15% Profit before Tax 21.1 20.5 26.3 57.9 83.6 PBT Margins % 9.13% 8.90% 12.66% 8.41
Slide 16: Company Overview
Company Overview
Slide 17: About Gufic Biosciences
About Gufic Biosciences Research based Pharmaceutical Company recognized for its innovative, high quality Pharmaceuticals Nutraceuticals, Natural Herbal products One of the Largest Manufacturers of Lyophilized Injections in India with a wide range of products in various therapy areas INTERNATIONAL B
Slide 18: World Class Manufacturing Infrastructure
World Class Manufacturing Infrastructure Unit - I at Navsari Unit - II at Navsari Gufic - Belgaum Botulinum Toxin Facility Lyophilized Injectables Facility Natural Products Facility Lyophilized/Powder Injectables Facility Capability to manufacture Liposomal Natural Products (Topical/Liquid) Amphoter
Slide 19: New Manufacturing Infrastructure
New Manufacturing Infrastructure Unit - III at Indore Penem Block UPDATE ON CAPEX Indore Lyophilized/Powder Injectables Dedicated facility for Penem Commercial Production Achieved Facility Carbapenems (Lyophilized / Dry Capability to cater to regulated Powder Inj / Oral Solids / Dual markets such as
Slide 20: Botulinum Toxin Facility
Botulinum Toxin Facility Gufic has built a state-of-the-art manufacturing facility for Botulinum Toxin in Navsari Gufic has partnered with Prime Bio, USA for manufacturing Botulinum Toxin API and formulation Gufic is equipped with all the necessary analytical testing procedures for safety and effica
Slide 21: Consolidating the Domestic Branded Business
Consolidating the Domestic Branded Business Products CRITICAL CARE INFERTILITY MASS SPECIALITY 100+ SKU’s 200+ Field Force: 250 Therapy Areas: Antibacterial, Field Force: >150 Therapy Areas: Hormones, Field Force: >180 Therapy Areas: Anti Infectives, Antifungal, Pain Management, Recombinant Products
Slide 22: Expanding Creditability in CMO Business
Expanding Creditability in CMO Business Offer CMO services for India and 70+ 150+ Products Reliable CMO service for quality products over a Global Markets Companies across multiple therapy areas decade One of the Largest Supplier of Formulations Liposomal Doxycycline Tigecycline Gonadotropins Micafu
Slide 23: Expanding Geographical Reach
Expanding Geographical Reach 130+ Products registered globally (in 15+ countries) 150+ Products in pipeline for registration (in 30+ countries) CANADA | COSTA RICA | PANAMA | COLUMBIA | CHILE | LATVIA | LITHUANIA | BELARUS | GERMANY | AUSTRIA | PORTUGAL | MOROCCO ALGERIA | DOMINICAN REPUBLIC | VENEZ
Slide 24: Building API Capabilities
Building API Capabilities Special Facility dedicated to API Focused on developing non The categories of API’s infringing, novel, cost manufactured are effective and scalable antifungals, antibacterial, chemical process for APIs, anesthetics and Peptides and Cyclopeptides intermediates for antifungal
Slide 25: Strong Partnership & Licensing Deals
Strong Partnership & Licensing Deals Through our collaborations with global partners that are European leader in IV drug researching to expand the frontiers of pharma and delivery systems. Collaborated biotechnology, Gufic will be a technology bridge to the with Gufic to launch Dual future of health
Slide 26: Extensive Sales, Distribution and IT Infrastructure
Extensive Sales, Distribution IT Infrastructure in India 2 Central Warehouses Pan India Presence with a located in North Delhi and field force of 1,000+ West Bhiwandi IT Infrastructure 23 Carrying & Forwarding Retail coverage of more than (C&F) agents across India Integrated IT Systems with Sales 1,
Slide 27: Growth Levers
Growth Levers 1 2 3 INTERNATIONAL INDIA BUSINESS CMO BUSINESS BUSINESS • Consolidation of the Critical Care Infertility • Expand our presence in regulated • Scale up the manufacturing capacity business markets such as US EU • Entry into new therapy areas Dermatology - • Consolidation of the clients
Slide 28: Our Robust R&D and Clinical team to augment growth
Our Robust R&D and Clinical team to augment growth Research & Development (R&D) Clinical Team State-of-the-art R&D Facility in Navsari, Gujarat with expertise in Formulation Development Technology Transfer API Development Patents in various therapy areas Granted: 5 Filed/In-process of filling : 8 Ma
Slide 29: Historical Financials
Historical Financials
Slide 30: Historical Financials
Historical Financials Particulars (Rs. Crs.) 9M FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 Total Revenue 692.2 823.4 808.8 693.2 782.3 491.4 384.6 359.5 EBITDA 108.2 140 149.5 137.2 151.1 87.7 57.9 56.7 EBITDA Margin % 15.63% 17.00% 18.48% 19.79% 19.31% 17.85% 15.05% 15.77% Profit before Tax 57.9 94.4
Slide 31: Historical Balance Sheet (Equity & Liabilities)
Historical Balance Sheet (Equity & Liabilities) EQUITY & LIABILITIES (Rs. Crs.) Sep-25 Mar-25 Mar-24 Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Equity Share Capital 10 10 10 9.7 9.7 9.7 9.7 7.8 Other Equity 618.5 591.3 522.5 338.1 259.4 163.7 119.6 67.6 Total Equity 628.5 601.3 532.5 347.8 269.1 173.4 129.3
Slide 32: Historical Balance Sheet (Assets)
Historical Balance Sheet (Assets) ASSETS (Rs. Crs.) Sep-25 Mar-25 Mar-24 Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Non-Current Assets Property, plant and equipment 467.6 475.2 138.3 126.8 105.5 93.8 72.7 70.3 Intangible assets 6.3 6.3 5.6 0.7 0.6 0.4 0.6 0.4 Capital work-in-progress 24.0 21.8 307.1 169.6 4
Slide 33: Historical Cash Flows
Historical Cash Flows Cash Flow Statement (Rs. Crs.) H1 FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 Net Profit Before Tax 36.8 94.4 115.7 106.7 126.9 57.7 30.1 35.3 Adjustments for: Non - Cash Items / Other Investment or 33.5 43.8 34.1 29.6 23.2 30.8 24.7 13.4 Financial Items Operating profit before wor
Slide 34: Thank You
THANK YOU Company: Gufic Biosciences Limited CIN: L24100MH1984PLC033519 Mr. Avik Das – Investor Relations avik.das@guficbio.com Tel: +91 22 67261000